<< Back to News

New FDA Approval for Pfizer's SUTENT®

Pfizer Oncology is proud to announce that SUTENT® (sunitinib malate) has been approved for adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy. SUTENT is the first approved treatment for patients with RCC in this setting.

For patients requiring financial assistance, Pfizer Oncology has support programs that may be able to help. You can learn more at the product website SUTENT.com.

Visit SUTENT.com to:

- Read updated full Prescribing Information

- Find out about access and coverage support for your patients